|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1050 K STREET, NW, #800 |
Address2 | |
City | WASHINGTON |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 16293-12
|
||||||||
|
6. House ID# 314610000
|
TYPE OF REPORT | 8. Year | 2013 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: William J. Schuyler, Vice President, Government Relations |
Date | 01/17/2014 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 2410 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act of 2014; provisions relating to FDA regulation and funding, sequestration, drug importation
H.J. Res. 59 - FY 14 Continuing Resolution; provisions related to the implementation of the Budget Control Act of 2011: Public Law No. 112-25, funding for the Biomedical Advanced Research and Development Authority (BARDA)
S. 1284 - Labor, Health and Human Services, Education and Related Agencies Appropriations Act of 2014; provisions related to ADAP, BARDA and Section 317
FY 14 Omnibus Appriopriations Act; provisions related to FDA and HHS funding
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William |
Schuyler |
|
|
|
Sarah |
Walsh |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Joseph |
McGowan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R. 2582 - PATENT Jobs Act; provisions related to patent user fees
H.R. 2766 - STOP Act; provisions related to business method patents
H.R. 3309 - Innovation Act; provisions related to patent litigation reform
H.R. 3349 - Innovation Protection Act ; provisions related to PTO fee diversion
H.R. 3540 - Demand Letter Transparency Act
S. 214 - The Preserve Access to Affordable Generics Act; provisions relating to patent settlements
S. 504 - Fair and Immediate Release of Generic Drugs Act; provisions related to patent settlements
S. 866 - Patent Quality Improvement Act of 2013; Business methods patents provisions
Biopharmaceutical innovation policy issues
Biologics data protection issues
Counterfeit drug issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William |
Schuyler |
|
|
|
Sarah |
Walsh |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Joseph |
McGowan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code DEF
16. Specific lobbying issues
H.R. 1960 - National Defense Authorization Act of 2014; provisions related to proposed judiciary amendment
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sarah |
Walsh |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 3204 - Drug Quality and Security Act; provisions relating to pharmacy compounding and supply chain
H.R. 6584 - Verifying Authority and Legality in Drug Compounding Act; provisions relating to drug compounding
H.R. 3742 - Antibiotic Development to Advance Patient Treatment Act
S. 957 - Drug Supply Chain Security Act; provisions related to supply chain security
S. 959 - Pharmaceutical Compounding Quality and Accountability Act; provisions related to pharmaceutical compounding
S. 1165 - Access to Appropriate Immunizations for Veterans Act of 2013; provisions related to extending VA performance measure to include all federally recommended vaccine
S. 610 - Family Health Care Flexibility Act; provisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts
H.R. 1248 - Family Health Care Flexibility Act; provisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts
H.R. 2725 - Food and Drug Administration Safety Over Sequestration Act of 2013; provisions related to FDA user fees
Implementation issues relating to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including Standards Related to Essential Health Benefits, Actuarial Value, and Accreditation rulemaking
FDA special medical use; issues related to limited population antibacterial drug approval pathway
FDA accelerated approval policy issues
Comparative effectiveness policy issues
Biopharmaceutical innovation policy issues
Pharmaceutical supply chain security issues
340B policy issues
Implementation issues relating to the Physician Payment Sunshine Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William |
Schuyler |
|
|
|
Sarah |
Walsh |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Joseph |
McGowan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 351 - Protecting Seniors' Access to Medicare Act of 2013; provisions related to the Independent Payment Advisory Board
H.R. 928 - Medicare Prescription Drug Savings and Choice Act of 2013; provisions related to Medicare Part D
H.R. 1024 - Medication Therapy Empowerment Act of 2013; provisions related to Part D issues
H.R. 1588 - Medicare Drug Savings Act of 2013; provisions related to Part D issues
H.R. 2810 - Medicare Patient Access and Quality Improvement Act of 2013
S. 117 - Medicare Prescription Drug Price Negotiation Act of 2013; provisions related to Part D issues
S. 351 - Protecting Seniors' Access to Medicare Act of 2013; provisions related to the Independent Payment Advisory Board
S. 408 - Medicare Prescription Drug Savings and Choice Act of 2013; provisions related to Medicare Part D
S. 557 - Medication Therapy Empowerment Act of 2013; provisions related to Part D issues
S. 740 - Medicare Drug Savings Act of 2013; provisions related to Part D issues
Dual eligibles coordination policy issues
Deficit reduction policy issues ; issues related to Medicare
Implementation Issues relating to the Physician Payment Sunshine Act
Vaccine access and coverage issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William |
Schuyler |
|
|
|
Sarah |
Walsh |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Joseph |
McGowan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Tax reform policy issues; issues related to corporate tax reform
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William |
Schuyler |
|
|
|
Sarah |
Walsh |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Joseph |
McGowan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAR
16. Specific lobbying issues
H.R. 6727; U.S. Job Creation and Manufacturing Competitiveness Act of 2013; provisions related to the temporary duty suspension for preparations, such as tablets or chewing gum, intended to assist smokers to stop smoking (provided for in subheading
2106.90.99)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Trans-Pacific Strategic Economic Partnership Agreement (TPP); provisions related to intellectual property, market access and public health issues
Transatlantic Trade and Investment Partnership (TTIP); provisions related to market access intellectual property, regulatory harmonization and other issues
India innovation, IP and market access issues
International market access and intellectual property issues
Trade Promotion Authority; provisions relations to pharmaceutical IP
Canada IP and market access issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Commerce - Dept of (DOC), State - Dept of (DOS), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William |
Schuyler |
|
|
|
Sarah |
Walsh |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Stephen |
Scango |
|
|
|
Joseph |
McGowan |
|
|
|
Shira |
Kilcoyne |
|
|
|
Edyta |
Wiesner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |